Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer

Gilberto de Castro; I Kudaba; YL Wu; G Lopes; DM Kowalski; HZ Turna; C Caglevic; L Zhang; B Karaszewska; KK Laktionov; V Srimuninnimit; I Bondarenko; K Kubota; R Mukherjee; JX Lin; F Souza; TSK Mok; BC Cho

doi:10.1136/jitc-2021-SITC2021.363

Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer

Gilberto de Castro
, I Kudaba
, YL Wu
, G Lopes
, DM Kowalski
, HZ Turna
, C Caglevic
, L Zhang
, B Karaszewska
, KK Laktionov
, V Srimuninnimit
, I Bondarenko
, K Kubota
, R Mukherjee
, JX Lin
, F Souza
, TSK Mok
, BC Cho

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	363
Pages (from-to)	A390
Journal	Journal for ImmunoTherapy of Cancer
Volume	9
Issue number	Suppl.2
DOIs	https://doi.org/10.1136/jitc-2021-SITC2021.363
Publication status	Published - Nov 2021
Externally published	Yes
Event	The Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting - Washington (Virtual), United States Duration: 12 Nov 2021 → 14 Nov 2021 Conference number: 36 https://www.sitcancer.org/2021/program/annual-meeting

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1136/jitc-2021-SITC2021.363

Cite this

de Castro, G., Kudaba, I., Wu, YL., Lopes, G., Kowalski, DM., Turna, HZ., Caglevic, C., Zhang, L., Karaszewska, B., Laktionov, KK., Srimuninnimit, V., Bondarenko, I., Kubota, K., Mukherjee, R., Lin, JX., Souza, F., Mok, TSK., & Cho, BC. (2021). Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer. Journal for ImmunoTherapy of Cancer, 9(Suppl.2), A390. Article 363. https://doi.org/10.1136/jitc-2021-SITC2021.363

@article{6edefe742c6c4bd29330f67711b0c398,

title = "Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer",

author = "\{de Castro\}, Gilberto and I Kudaba and YL Wu and G Lopes and DM Kowalski and HZ Turna and C Caglevic and L Zhang and B Karaszewska and KK Laktionov and V Srimuninnimit and I Bondarenko and K Kubota and R Mukherjee and JX Lin and F Souza and TSK Mok and BC Cho",

year = "2021",

month = nov,

doi = "10.1136/jitc-2021-SITC2021.363",

language = "English",

volume = "9",

pages = "A390",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BMJ Publishing Group",

number = "Suppl.2",

note = "The Society for Immunotherapy of Cancer{\textquoteright}s (SITC) 36th Anniversary Annual Meeting ; Conference date: 12-11-2021 Through 14-11-2021",

url = "https://www.sitcancer.org/2021/program/annual-meeting",

}

de Castro, G, Kudaba, I, Wu, YL, Lopes, G, Kowalski, DM, Turna, HZ, Caglevic, C, Zhang, L, Karaszewska, B, Laktionov, KK, Srimuninnimit, V, Bondarenko, I, Kubota, K, Mukherjee, R, Lin, JX, Souza, F, Mok, TSK & Cho, BC 2021, 'Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer', Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl.2, 363, pp. A390. https://doi.org/10.1136/jitc-2021-SITC2021.363

Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer. / de Castro, Gilberto; Kudaba, I; Wu, YL et al.
In: Journal for ImmunoTherapy of Cancer, Vol. 9, No. Suppl.2, 363, 11.2021, p. A390.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Keynote-042 5-year Survival Update

T2 - The Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting

AU - de Castro, Gilberto

AU - Kudaba, I

AU - Wu, YL

AU - Lopes, G

AU - Kowalski, DM

AU - Turna, HZ

AU - Caglevic, C

AU - Zhang, L

AU - Karaszewska, B

AU - Laktionov, KK

AU - Srimuninnimit, V

AU - Bondarenko, I

AU - Kubota, K

AU - Mukherjee, R

AU - Lin, JX

AU - Souza, F

AU - Mok, TSK

AU - Cho, BC

N1 - Conference code: 36

PY - 2021/11

Y1 - 2021/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000774877500352&DestLinkType=FullRecord&DestApp=WOS

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000774877500352

U2 - 10.1136/jitc-2021-SITC2021.363

DO - 10.1136/jitc-2021-SITC2021.363

M3 - Meeting Abstract

SN - 2051-1426

VL - 9

SP - A390

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - Suppl.2

M1 - 363

Y2 - 12 November 2021 through 14 November 2021

ER -

Keynote-042 5-year Survival Update: Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated, Pd-L1positive, Locally Advanced Or Metastatic Non-small-cell Lung Cancer

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this